A Comparative study between the diagnostic ability of EUS-FNA with 22-gauge franseen needle and that with 19-gauge franseen needle for autoimmune pancreatitis

A Comparative study between the diagnostic ability of EUS-FNA with 22-gauge franseen needle and that with 19-gauge franseen needle for autoimmune pancreatitis - AIP-acquire 19G vs 22G study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042998

Enrollment

Registered

2021-01-13

Start date

2019-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune pancreatitis

Interventions

A 19-gauge franseen needle is used in EUS-FNA prior to a 22-gauge franseen needle A 22-gauge franseen needle is used in EUS-FNA prior to a 19-gauge franseen needle

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Need for pathological confirmation of type 1 autoimmune pancreatitis

Exclusion criteria

Exclusion criteria: Coagulopathy Severe comorbidity(ASA class3 or more) Low performance status(PS 4) Severe hemodynamic disease or respiratory disease Pregnancy or breast-feeding Not suitable for the study

Design outcomes

Primary

Measure	Time frame
Pathological diagnostic rate of autoimmune pancreatitis	—

Countries

Japan

Contacts

Public ContactToshifumi Kin

Teine-Keijinkai Hospital Center for Gastroenterology

kin_toshifumi@yahoo.co.jp011-681-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026